- Home
- HIFS vs CELC Comparison
HIFS vs CELC Comparison
Compare HIFS & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIFS
- CELC
- Stock Information
- Founded
- HIFS 1834
- CELC 2011
- Country
- HIFS United States
- CELC United States
- Employees
- HIFS N/A
- CELC N/A
- Industry
- HIFS Major Banks
- CELC Medical Specialities
- Sector
- HIFS Finance
- CELC Health Care
- Exchange
- HIFS Nasdaq
- CELC Nasdaq
- Market Cap
- HIFS 506.7M
- CELC 594.7M
- IPO Year
- HIFS N/A
- CELC 2017
- Fundamental
- Price
- HIFS $273.93
- CELC $12.66
- Analyst Decision
- HIFS
- CELC Strong Buy
- Analyst Count
- HIFS 0
- CELC 6
- Target Price
- HIFS N/A
- CELC $29.17
- AVG Volume (30 Days)
- HIFS 14.1K
- CELC 257.7K
- Earning Date
- HIFS 10-11-2024
- CELC 11-14-2024
- Dividend Yield
- HIFS 0.92%
- CELC N/A
- EPS Growth
- HIFS N/A
- CELC N/A
- EPS
- HIFS 10.55
- CELC N/A
- Revenue
- HIFS $58,408,000.00
- CELC N/A
- Revenue This Year
- HIFS N/A
- CELC N/A
- Revenue Next Year
- HIFS N/A
- CELC N/A
- P/E Ratio
- HIFS $25.97
- CELC N/A
- Revenue Growth
- HIFS N/A
- CELC N/A
- 52 Week Low
- HIFS $150.11
- CELC $11.51
- 52 Week High
- HIFS $300.00
- CELC $22.19
- Technical
- Relative Strength Index (RSI)
- HIFS 53.18
- CELC 28.22
- Support Level
- HIFS $250.04
- CELC $15.33
- Resistance Level
- HIFS $300.00
- CELC $16.14
- Average True Range (ATR)
- HIFS 8.94
- CELC 0.97
- MACD
- HIFS 0.39
- CELC -0.28
- Stochastic Oscillator
- HIFS 47.82
- CELC 22.85
About HIFS Hingham Institution for Savings
Hingham Institution for Savings is a savings bank based in Hingham, Massachusetts, and is involved in the business of residential and commercial real estate mortgage lending and also financial and banking services. The bank's financial services include personal checking accounts, personal mortgages, home equity lines of credit, money market accounts, savings accounts, certificates of deposit, and business checking accounts. Its lending portfolio mainly encompasses commercial real estate, residential owner-occupied real estate, and loans for the construction of residential real estate.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.